Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02391480 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer
A Phase 1 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 1
- Development phase
- 128
- Enrollment target
NCT02391480 is a Phase 1 study that has completed, run by AbbVie. The registered enrollment target is 128 participants.
The verdict
NCT02391480, a Phase 1 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 128 participants
- Enrollment target
Study Summary
This is a Phase 1, first-in-human, dose escalation study in participants with advanced solid tumors to determine the pharmacokinetics, maximum tolerated dose and the recommended Phase 2 dose of ABBV-075 at different monotherapy dosing schedules. In addition the study will evaluate the safety. tolerability and the pharmacokinetics of ABBV-075 monotherapy or combination therapy in disease specific expansion cohorts.
Interventions
- DRUG Venetoclax
- DRUG ABBV-075
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2015-04-14 |
| Est. Completion | 2019-07-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02391480
The ClinicalTrials.gov registry entry for NCT02391480 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 128 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Venetoclax is the first listed.
NCT02391480 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02391480 about?
NCT02391480 is a clinical study titled "A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer". This is a Phase 1, first-in-human, dose escalation study in participants with advanced solid tumors to determine the pharmacokinetics, maximum tolerated dose and the recommended Phase 2 dose of ABBV-075 at different monotherapy dosing schedules. In addition the study will evaluate the safety. tolera...
What is the current status of trial NCT02391480?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 128 participants. The study started on 2015-04-14. Estimated completion is 2019-07-05.
What interventions are being tested in trial NCT02391480?
The interventions under investigation include: Venetoclax (DRUG), ABBV-075 (DRUG).
Who is sponsoring clinical trial NCT02391480?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.